EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-12-13

Reporting Person: Paggiarino Dario A. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-13	Common Stock	M	1458.00	$10.13	Acquired	27165.00	Direct
2023-12-13	Common Stock	S	1458.00	$20.00	Disposed	25707.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-13	Stock Option (Right to Buy)	$10.13	M	1458.00	Disposed	2032-02-09	Common Stock (1458.00)	Direct

Footnotes

F1: The option to purchase vests and becomes exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.